Molecular basis of eIF3a gene in therapeutic response of lung cancer patients to platinum-based chemotherapy

被引：0
|
作者：
Yin, Ji-ye [1 ]
Xu, Xiao-jing [1 ]
Zhou, Hong-hao [1 ]
Liu, Zhao-qian [1 ]
机构：
[1] Cent S Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha 410078, Hunan, Peoples R China
来源：
ACTA PHARMACOLOGICA SINICA | 2013年 / 34卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [1] Effect of eIF3a on Response of Lung Cancer Patients to Platinum-Based Chemotherapy by Regulating DNA Repair
    Yin, Ji-Ye
    Shen, Jie
    Dong, Zi-Zheng
    Huang, Qiong
    Zhong, Mei-Zuo
    Feng, De-Yun
    Zhou, Hong-Hao
    Zhang, Jian-Ting
    Liu, Zhao-Qian
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (13) : 4600 - 4609
  • [2] The A/G allele of eIF3a rs3740556 predicts platinum-based chemotherapy resistance in lung cancer patients
    Xu, Xiaojing
    Han, Lifang
    Yang, Huaping
    Duan, Li
    Zhou, Boting
    Zhao, Yingchun
    Qu, Jian
    Ma, Rui
    Zhou, Honghao
    Liu, Zhaoqian
    [J]. LUNG CANCER, 2013, 79 (01) : 65 - 72
  • [3] Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients
    Yin, Ji-ye
    Meng, Xiang-guang
    Qian, Chen-yue
    Li, Xiang-ping
    Chen, Juan
    Zheng, Yi
    Liu, Rong
    Zhou, Hong-hao
    Liu, Zhao-qian
    [J]. ACTA PHARMACOLOGICA SINICA, 2015, 36 (03) : 375 - 384
  • [4] Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients
    Ji-ye Yin
    Xiang-guang Meng
    Chen-yue Qian
    Xiang-ping Li
    Juan Chen
    Yi Zheng
    Rong Liu
    Hong-hao Zhou
    Zhao-qian Liu
    [J]. Acta Pharmacologica Sinica, 2015, 36 : 375 - 384
  • [5] Markers of response to platinum-based chemotherapy in lung cancer
    Barr, Martin P.
    MacDonagh, Lauren
    O'Byrne, Kenneth J.
    [J]. LUNG CANCER MANAGEMENT, 2013, 2 (03) : 227 - 239
  • [6] HADHA is a Potential Predictor of Response to Platinum-based Chemotherapy for Lung Cancer
    Kageyama, Taihei
    Nagashio, Ryo
    Ryuge, Shinichiro
    Matsumoto, Toshihide
    Iyoda, Akira
    Satoh, Yukitoshi
    Masuda, Noriyuki
    Jiang, Shi-Xu
    Saegusa, Makoto
    Sato, Yuichi
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (12) : 3457 - 3463
  • [7] Changes in Lung Function during Platinum-based Chemotherapy for Patients with Lung Cancer
    Goetschke, J.
    von Wachter, C.
    Sellmer, L.
    Mertsch, P.
    Kauffmann-Guerrero, D.
    Syunyaeva, Z.
    Alpay, N.
    Tufman, A.
    [J]. PNEUMOLOGIE, 2020, 74 : S54 - S54
  • [8] Thromboembolic events in lung cancer patients treated with platinum-based chemotherapy
    Rouis, Houda
    Kamoun, Hela
    Rejeb, Hadhemi
    Ben Tkhayat, Achraf
    Smadhi, Hanen
    Greb, Dorra
    Ben Abdelghaffar, Hajer
    Akrout, Ines
    Hassene, Hela
    Fekih, Leila
    Megdiche, Mohamed Lamine
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [9] Glutathione pathway pharmacogenomics and response to platinum-based chemotherapy of lung cancer.
    Moyer, A.
    Sun, Z.
    Jenkins, G.
    Batzler, A.
    Hildebrandt, M.
    Schaid, D.
    Yang, P.
    Weinshilboum, R.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S7 - S7
  • [10] Pharmacogenomics in lung cancer:: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy
    García-Campelo, R
    Alonso-Curbera, G
    Aparicio, LMA
    Rosell, R
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (12) : 2015 - 2026
12345